Anthropic reports early drug work and a Mithril acquisition

Anthropic said on Oct. 27, 2026 that it has research partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and that it has acquired Mithril Medicine. Enveda said a Claude review of 1,061 batch-record pages cut one timed review from almost 26 hours to just under three, and that a Module 2 draft took four hours versus about three months by hand. Anthropic said the work is mostly preclinical, did not disclose the Mithril terms, and said a human trial is a conditional target of late 2028 if the candidates hold up.